Cargando…

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia

The revised 2022 European LeukemiaNet (ELN) AML risk stratification system requires validation in large, homogeneously treated cohorts. We studied 1118 newly diagnosed AML patients (median age, 58 years; range, 18–86 years) who received cytarabine-based induction chemotherapy between 1999 and 2012 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rausch, Christian, Rothenberg-Thurley, Maja, Dufour, Annika, Schneider, Stephanie, Gittinger, Hanna, Sauerland, Cristina, Görlich, Dennis, Krug, Utz, Berdel, Wolfgang E., Woermann, Bernhard J., Hiddemann, Wolfgang, Braess, Jan, von Bergwelt-Baildon, Michael, Spiekermann, Karsten, Herold, Tobias, Metzeler, Klaus H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244159/ https://www.ncbi.nlm.nih.gov/pubmed/37041198 http://dx.doi.org/10.1038/s41375-023-01884-2

Ejemplares similares

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2020)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?
por: Rausch, Christian, et al.
Publicado: (2023)

P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING
por: Thieme, Susanne, et al.
Publicado: (2023)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
por: Prassek, Victoria V., et al.
Publicado: (2018)

Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML
por: Batcha, Aarif M. N., et al.
Publicado: (2022)

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
por: Rothenberg-Thurley, Maja, et al.
Publicado: (2018)

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
por: Hornung, Roman, et al.
Publicado: (2018)

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2018)

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
por: Schranz, Katrin, et al.
Publicado: (2018)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Long-term follow-up of cytogenetically normal CEBPA-mutated AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
por: Lengfelder, Eva, et al.
Publicado: (2012)

The clinical mutatome of core binding factor leukemia
por: Opatz, Sabrina, et al.
Publicado: (2020)

A three-gene expression-based risk score can refine the European LeukemiaNet AML classification
por: Wilop, Stefan, et al.
Publicado: (2016)

Plasticity in growth behavior of patients’ acute myeloid leukemia stem cells growing in mice
por: Ebinger, Sarah, et al.
Publicado: (2020)

Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia
por: Janke, Hanna, et al.
Publicado: (2014)

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
por: Hochhaus, A., et al.
Publicado: (2020)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
por: Cross, Nicholas C. P., et al.
Publicado: (2023)

Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2016)

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2018)

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia
por: Alachkar, Houda, et al.
Publicado: (2014)

S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Bill, Marius, et al.
Publicado: (2023)

Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
por: Reiter, K, et al.
Publicado: (2018)

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera
por: Tremblay, Douglas, et al.
Publicado: (2022)

Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia
por: Vaikari, Vijaya Pooja, et al.
Publicado: (2020)

Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs
por: Fiegl, Michael, et al.
Publicado: (2007)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet
por: Itzykson, Raphael, et al.
Publicado: (2018)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
por: Bataller, Alex, et al.
Publicado: (2022)

Loss of KDM6A confers drug resistance in acute myeloid leukemia
por: Stief, Sophie M., et al.
Publicado: (2019)

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
por: Wille, Kai, et al.
Publicado: (2023)

An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging
por: Vick, Binje, et al.
Publicado: (2015)

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
por: Mrózek, Krzysztof, et al.
Publicado: (2023)

Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet
por: van der Velden, Vincent H. J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e4aar2ho3aip74i5drr5ugril4